NICE issues first UK guidance for PMOS treatment

Summary

The National Institute for Health and Care Excellence has published the first national guidance for NHS treatment of polyendocrine metabolic ovarian syndrome (PMOS). The draft guidance, published on 1 July 2026, is the first of its kind for a UK population and addresses the management of PMOS, as well as common problems associated with it […] The post NICE issues first UK guidance for PMOS treatment appeared first on The Pharmaceutical Journal .

Source: The Pharmaceutical Journal

(0)

AI News Q&A (Free Content)

This content is freely available. No login required. Disclaimer: Following content is AI generated from various sources including those identified below. Always check for accuracy. No content here is an advice. Please use the contact button to share feedback about any inaccurate content generated by AI. We sincerely appreciate your help in this regard.

Q1: What is the significance of the new NICE guidance for the treatment of polyendocrine metabolic ovarian syndrome (PMOS) in the UK?

A1: The new guidance issued by NICE is significant as it is the first national guidance specifically for the treatment of PMOS in the UK. It aims to standardize the management of PMOS and address common associated problems like acne, hirsutism, and obstructive sleep apnea. This guidance highlights the importance of lifestyle management and recommends the off-label use of certain medications such as progestogens, combined oral contraceptives, and metformin to manage symptoms. The draft guideline is open for consultation until August 11, 2026, with final guidance expected in December 2026.

Q2: How does the NICE guideline propose to address the diagnosis and management of PMOS?

A2: The guideline proposes regular assessments of glycaemic status in individuals diagnosed with PMOS and recommends the use of HbA1c testing or fasting plasma glucose. It emphasizes the importance of not denying access to treatments like ovulation induction based on BMI alone if it is less than 40 kg/m2. The guideline also suggests the use of letrozole for those with anovulatory infertility. Recommendations also include monitoring for cardiometabolic risks and managing fertility problems.

Q3: What are the potential benefits of the NICE guideline on PMOS for healthcare providers and patients?

A3: For healthcare providers, the guideline provides a structured approach to diagnosing and managing PMOS, potentially improving consistency in care delivery. For patients, it can increase awareness of PMOS, support earlier diagnosis, and offer a variety of management strategies to control symptoms and reduce long-term health risks associated with PMOS, such as diabetes and cardiovascular diseases.

Q4: What does recent research suggest about the role of inflammation and immune dysfunction in the pathogenesis of PMOS?

A4: Recent research indicates that chronic immune dysfunction is a hallmark of PMOS. A study involving TLR4 knockout mice suggests that gut-derived bacterial endotoxins can breach intestinal barriers and cause systemic inflammation through Toll-like receptor 4 (TLR4). These findings suggest that TLR4-mediated inflammation could be targeted for anti-inflammatory treatments in women with PMOS, providing a novel approach to managing this condition.

Q5: How does the new guidance address the use of mechanical laser and light therapies for PMOS symptoms?

A5: The new NICE draft guideline does not recommend the use of mechanical laser and light therapies for reducing hair due to their cost-effectiveness concerns. It suggests that these therapies are not a cost-effective way of improving overall health and wellbeing, estimating a possible cost impact of up to £100 million per year if recommended widely.

Q6: What lifestyle modifications are recommended for managing PMOS according to the NICE guideline?

A6: The NICE guideline recommends lifestyle modifications such as maintaining a healthy weight, balanced diet, regular exercise, and monitoring mental health. For those planning a pregnancy, additional advice on weight, nutrition, sleep, and stress management is recommended to prevent more serious illnesses associated with PMOS.

Q7: How does the new NICE guidance aim to improve the awareness and consistency of PMOS care?

A7: The new NICE guidance aims to improve awareness by providing detailed diagnostic and management strategies for PMOS, which is expected to support earlier diagnosis and management. By standardizing care processes and recommendations, the guideline seeks to improve the consistency of care provided to patients across the NHS, thereby reducing the variability in treatment and outcomes.